MitochondrialEV · WEAK

NAD+

Endogenous coenzyme and electron carrier (not a peptide)

akaNicotinamide adenine dinucleotideNADβ-Nicotinamide adenine dinucleotide
Class
Coenzyme metabolite
Half-life
~2–4 hours
Route
Subcutaneous (SubQ)
Cadence
Multiple per week
Evidence
Weak / anecdotal

Overview

NAD+ is a small-molecule coenzyme found in every living cell—not a peptide. It sits at the center of energy metabolism, shuttling electrons in mitochondria and serving as a substrate for enzymes involved in DNA repair, gene expression, and aging pathways. NAD+ levels decline with age in many tissues, which has motivated interest in NAD+-boosting strategies.

The research market sells injectable NAD+ (subcutaneous or intramuscular) as a direct-delivery alternative to oral precursors like NMN or NR. The pitch: bypass gut degradation and raise cellular NAD+ faster. The problem: there are no published human pharmacokinetic or efficacy trials for injectable NAD+ itself. The entire evidence base for raising NAD+ in humans comes from oral precursor studies—NMN and NR—not from injecting the NAD+ molecule directly.

Oral NAD+ has poor bioavailability because the molecule is too large and unstable to cross the gut intact; it breaks down into precursors before absorption. Whether injecting NAD+ subcutaneously or intramuscularly actually raises intracellular NAD+ in the tissues that matter (brain, muscle, liver) has not been demonstrated in peer-reviewed human studies. The injectable NAD+ phenomenon is a wellness-clinic export with almost no formal clinical validation.

Safety considerations

A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.

  • Not approved by FDA, EMA, or any other regulator for human use. Sold in compounding pharmacies and wellness clinics as an unregulated product.
  • No published human pharmacokinetic, safety, or efficacy trials for injectable NAD+ itself. All human RCT evidence is for oral precursors (NMN, NR), not direct NAD+ injection.
  • Injection-site discomfort is the most commonly reported side effect in wellness settings; some users report brief fatigue or warmth after injection.

+ 3 more safety notes inside AIx Core →

Commonly monitored

Markers and signals people track when researching NAD+.

  • Subjective energy and cognitive clarity (the claimed benefits)
  • Injection-site reactions—redness, pain, swelling
  • Baseline and follow-up NAD+ metabolite panel (some labs offer this—validation is mixed)
  • Sleep quality and fatigue scales
  • Any unexplained nausea, flushing, or warmth post-injection

Frequently asked questions

What is NAD+?

Endogenous coenzyme and electron carrier (not a peptide). NAD+ is a small-molecule coenzyme found in every living cell—not a peptide. It sits at the center of energy metabolism, shuttling electrons in mitochondria and serving as a substrate for enzymes involved in DNA repair, gene expression, and aging pathways. NAD+ levels decline with age in many tissues, which has motivated interest in NAD+-boosting strategies.

How is NAD+ administered?

Subcutaneous (SubQ), typically multiple per week.

What is the half-life of NAD+?

~2–4 hours — Rapidly consumed by cellular NAD+ metabolizing enzymes; plasma half-life poorly characterized for injectable route.

Is NAD+ approved for human use?

NAD+ is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.

What does the evidence show for NAD+?

Evidence tier: Weak / anecdotal. All published human efficacy data for raising NAD+ are from oral precursors (NMN, NR), not injectable NAD+ itself. No peer-reviewed PK or tissue distribution data exist for injected NAD+ in humans.

What is commonly monitored when researching NAD+?

Commonly tracked markers + signals: Subjective energy and cognitive clarity (the claimed benefits), Injection-site reactions—redness, pain, swelling, Baseline and follow-up NAD+ metabolite panel (some labs offer this—validation is mixed), Sleep quality and fatigue scales, Any unexplained nausea, flushing, or warmth post-injection.

Related compounds

Open this in AIx Core for the full picture

Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.